Ruti Aga's Six-Year Ban: A Forged Prescription, and a Drug the Headlines Misclassified

Two and four, six in all. That is the entire arithmetic of Ruti Aga's case as set out in Thursday's Athletics Integrity Unit (AIU) statement — two years for the presence of a prohibited substance, four years for tampering. The substance that opened the file was methylprednisolone. A knee injection. The cheapest, most ordinary, least dramatic treatment available to a distance runner.

The drug did not end Aga's career. A piece of paper did. The "doctor" who signed the prescription was a family member with no medical registration, attached to a clinic that did not exist. Questioned, the person offered the defence that an "old prescription pad from a former workplace" had been used. The clinic whose pad it supposedly was denied flatly that any such pad had ever existed there.

Three separate verifications, three failures. This case will be remembered in the anti-doping archive not for the substance that was caught but for the document.

Aga is not a minor name. She won the 2026 Tokyo Marathon and finished second at three World Marathon Majors — 2:18:34 for second in Berlin 2026, 2:20:40 for first in Tokyo 2026. That is the band at which Ethiopian women's marathon depth begins, not where it ends. At 32 she was entering the back half of a career — the corner just past the peak, where distance runners typically start bargaining with their knees.

The sample that returned positive was collected after she won a half marathon in China in March. She has been provisionally suspended since 10 September, and the six-year ban is backdated to the same date. The mark from that race is nowhere in the source. No split, no field strength, no wind. So resist reading form off the win — the split time is a story, not a verdict.

A technical correction is necessary here, because early reports called this a "prohibited steroid." Methylprednisolone is not an anabolic steroid. It sits in class S9 of the WADA Prohibited List — a glucocorticoid. Class S1 is where anabolic agents live, and the two classes stand on entirely different legal ground. S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. The same knee injection administered in training is fully legal. A violation arises only if residue is present inside the competition window, which for a road race opens at 23:59 the night before. That is the technical hinge the whole case turns on, and it is precisely what the "steroid" framing erases.

The sanction architecture is standard, not exceptional. Two years for presence — the tariff where intent is unproven. Four years for tampering — the Code's default. Six in total. What matters most is what the arithmetic excludes: the panel declined the no-significant-fault mitigation that would otherwise have cut the presence sanction. And the irony runs the other way too — forged documentation is itself circumstantial evidence of concealment, yet it did not inflate the presence charge. It was punished separately, at the tampering end.

The real question is why the defence collapsed. Because the substance is S9, Aga had a legitimate argument available: route, timing and medical necessity. Intra-articular injections for knee synovitis are routine practice among distance runners. With genuine medical records, a real clinic and a registered physician, the case might never have reached a presence violation at all, and tampering would never have arisen. By manufacturing the prescription, she destroyed the only defence that could have worked.

This is where the story stops being individual carelessness and becomes a picture of a system. An athlete with a team physician has the treatment documented in advance — either a TUE is secured, or the WADA route-specific washout is observed. Neither happened here. Instead a family member became the doctor. That is not a filing error; it is the signature of an athlete operating without credentialed medical support.

In July 2026 I talked my way into the mixed zone at Kalinga Stadium during the Asian Athletics Championships with no broadcaster credential, and ran a self-funded Facebook Live interview with a Railways long jumper about sports-quota jobs. Six thousand people watched. What I understood that day was that the question in Indian athletics is not "who won" but "who pays." In Aga's case the same question arrives in a different shape — who arranges the treatment, and who manufactures its paperwork.

The real professional contract in East African road running is not prize money; it is appearance fees. Between Majors and label races, the Chinese half-marathon circuit is a fat, low-risk income tier. It is also where the AIU's highest-yield testing now happens. The appearance-fee economy and the testing economy are colliding in the same races, and the athlete without formal medical backup falls first in that collision.

The effect on Ethiopian selection arithmetic is zero. Women's marathon depth there is so extreme that a 32-year-old running 2:18–2:20 is not automatically selectable. Her three Major silver medals are commercial-tier results, not converted championship podiums. She returns at roughly 38, carrying a doping record — near-invisibility in this event.

For an Indian reader a parallel line extends here, and I want to draw it carefully. The 2026 Commonwealth and Asian Games relay golds were never stripped, and in the same period six athletes received CAS-confirmed bans. Both truths have to be held at once — neither a clean golden age nor a rubble heap. Some careers are built in the fourth-place archive; this case belongs to the other half of that archive, where what hurts is not the missing medal but the missing document.

Now the part that gets skipped. Six years has been imposed for a substance with no proven endurance benefit. A glucocorticoid reduces pain and swelling; it does not build the muscle that the word "doping" conjures. Two readings are ready-made. One: proof of AIU rigour. Two: proof of disproportionate enforcement against African road runners.

Mine is a third. The asymmetry is not in the length of the ban but in the infrastructure. A Norwegian or British athlete with a federation doctor and a lawyer on retainer files a TUE for the same injection — clean paper, closed case. An Ethiopian athlete with a family member on call forges a prescription — dirty paper, six years. One drug, two outcomes. The difference is not pharmacological; it is clerical.

The second point tells us where anti-doping is heading. The AIU's frontier has shifted from detection to document verification. The four-year sanction came not from a seized document but from statements made in an interview. That is a new category of risk for athletes — language, translation and the conditions of questioning now determine the length of a ban.

And a warning aimed at myself: do not mistake one case for a system. My instinct is to see a number leap off the page and call it destiny — here the number is six. Case clustering is a different thing from a single case, and the repeated appearance of document forgery in East African road-running files is a genuine signal. A case is a story, not a verdict.

Three things to watch. First, whether the March race result and its prize money are annulled — standard AIU practice, but unstated in the release. Second, whether the investigation reaches the agent or management; only the family member is named. Third, why the Ethiopian federation is silent — there is not a single statement from it anywhere in this file.

The 65th minute is where the broadcast learns to breathe. In anti-doping coverage that minute never arrives — we print the ban, then forget it by morning. The real question is not the one the AIU asked. It is: who arranged the treatment on that knee, and who paid the bill? The day we answer that, we will know whether this is one athlete's story or an entire cohort's.